Gadolinium-based MRI contrast agents have been proving to carry great risk of nephrogenic systemic fibrosis (NSF). This has caused the U.S. Food and Drug Administration (FDA) to announce warning labels updates on three of these agents. The three agents are Magnevist, sold by Bayer Healthcare Pharmaceuticals of Wayne, NJ; Omniscan, marketed by GE Healthcare of Chalfont St. Giles, U.K.; and Optimark, sold by Covidien of Dublin, Ireland.
In 2007, FDA has required that a black box warning labels should be carried on all gadolinium-based MRI contrast agents available at that time, indicating that they carry risk of developing NSF for patients using them...
No comments:
Post a Comment